Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Dupuis, R. Casasnovas, F. Morschhauser, H. Ghesquières, C. Thieblemont, V. Ribrag, H. Tilly, B. Coiffier (2011)
Early Results of a Phase Ib/II Dose-Escalation Trial of Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphomas (PTCL)Blood, 118
L. Vassen, Wafaâ Lemsaddek, M. Trudel, T. Möröy (2011)
Growth Factor Independence 1b (Gfi1b) Is Required for the Regulation of Fetal Globin Genes in Both Fetal and Adult Erythroid CellsBlood, 118
M. Fang, B. Storer, E. Estey, M. Othus, Lisa Zhang, B. Sandmaier, F. Appelbaum (2011)
Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation.Blood, 118 6
P. Piccaluga, M. Laginestra, M. Rossi, A. Leo, D. Gibellini, A. Gazzola, M. Sapienza, C. Agostinelli, S. Pileri (2011)
Identification of Differentially Expressed miRNAs in Peripheral t-Cell LymphomasBlood, 118
M. Djokic (2009)
ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma ProjectYearbook of Pathology and Laboratory Medicine, 2009
E. Martín-Sánchez, S. Rodríguez-Pinilla, M. Sánchez-Beato, Beatriz Domínguez-González, M. Wozniak, M. Mollejo, J. Alvés, J. Rodríguez-Peralto, J. Menárguez, J. Cigudosa, P. Ortiz-Romero, Juan García, J. Bischoff, M. Piris (2011)
PIM Kinases Inhibition, a Rational Strategy in Peripheral T-Cell Lymphomas,Blood, 118
B. Coiffier, B. Pro, H. Prince, F. Foss, L. Sokol, M. Greenwood, D. Caballero, P. Borchmann, F. Morschhauser, M. Wilhelm, L. Pinter-Brown, S. Padmanabhan, A. Shustov, J. Nichols, S. Carroll, J. Balser, Barbara Balser, S. Horwitz (2012)
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 6
K. Savage, N. Harris, J. Vose, F. Ullrich, E. Jaffe, J. Connors, L. Rimsza, S. Pileri, M. Chhanabhai, R. Gascoyne, J. Armitage, D. Weisenburger (2008)
ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.Blood, 111 12
F. d'Amore, T. Relander, G. Lauritzsen, E. Jantunen, H. Hagberg, H. Anderson, H. Holte, A. Österborg, M. Merup, P. Brown, O. Kuittinen, M. Erlanson, B. Østenstad, U. Fagerli, O. Gadeberg, C. Sundström, J. Delabie, E. Ralfkiaer, M. Vornanen, Helle Toldbod (2011)
High-Dose Chemotherapy and Autologuos Stem Cell Transplantation in Previously Untreated Peripheral T-Cell Lymphoma - Final Analysis of a Large Prospective Multicenter Study (NLG-T-01)Blood, 118
A. Gallamini, F. Zaja, C. Patti, A. Billio, M. Specchia, A. Tucci, A. Levis, A. Manna, V. Secondo, L. Rigacci, A. Pinto, E. Iannitto, V. Zoli, P. Torchio, S. Pileri, C. Tarella (2007)
Alemtuzumab ( Campath-1 H ) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma : results of a GITIL ( Gruppo Italiano Terapie Innovative nei Linfomi ) prospective multicenter trial
O. O’Connor, B. Pro, L. Pinter-Brown, N. Bartlett, L. Popplewell, B. Coiffier, M. Lechowicz, K. Savage, A. Shustov, C. Gisselbrecht, E. Jacobsen, P. Zinzani, R. Furman, A. Goy, C. Haioun, M. Crump, J. Zain, E. Hsi, A. Boyd, S. Horwitz (2011)
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 9
P. Reimer, T. Rüdiger, E. Geissinger, F. Weissinger, C. Nerl, N. Schmitz, A. Engert, H. Einsele, H. Müller-hermelink, M. Wilhelm (2009)
Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 1
K. Dunleavy, M. Shovlin, S. Pittaluga, C. Grant, S. Steinberg, E. Jaffe, W. Wilson (2011)
DA-EPOCH Chemotherapy Is Highly Effective in ALK-Positive and ALK-Negative ALCL: Results of a Prospective Study of PTCL Subtypes in AdultsBlood, 118
A. Gallamini, F. Zaja, C. Patti, A. Billio, M. Specchia, A. Tucci, A. Levis, A. Manna, V. Secondo, L. Rigacci, A. Pinto, E. Iannitto, V. Zoli, P. Torchio, S. Pileri, C. Tarella (2007)
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.Blood, 110 7
W. Hobbs, Rebecca Penkala, E. Moore, José López (2011)
Cocaine and Certain of Its Long-Acting Metabolites Stimulate Endothelial Cell Von Willebrand Factor SecretionBlood, 118
E. Marchi, M. Kalac, D. Bongero, Christine McIntosh, Laura Fogli, L. Scotto, M. Rossi, P. Zinzani, S. Pileri, P. Piccaluga, O. O’Connor (2011)
Combination of Epigenetic Agents Synergistically Reverse the Malignant Phenotype in Models of T-Cell LymphomaBlood, 118
José Rodríguez, E. Conde, A. Gutiérrez, R. Arranz, A. León, J. Marín, M. Bendandi, C. Albó, M. Caballero (2007)
Frontline autologous stem cell transplantation in high‐risk peripheral T‐cell lymphoma: a prospective study from The Gel‐Tamo Study GroupEuropean Journal of Haematology, 79
E. Tucker, U. Marzec, Philberta Leung, S. Hanson, Norah Verbout, Sawan Hurst, O. McCarty, D. Gailani, A. Gruber (2011)
Apple Domain-Specific Anti-Factor XI Antibodies Inhibit Venous-Type Thrombosis with Improved Hemostatic Safety Profiles Compared to Enoxaparin in PrimatesBlood, 118
R. Advani, A. Shustov, P. Brice, N. Bartlett, J. Rosenblatt, T. Illidge, J. Matous, R. Ramchandren, M. Fanale, J. Connors, Yin Yang, D. Kennedy, B. Pro (2011)
Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study UpdateBlood, 118
SH Swerdlow, E Campo, NL Harris (2008)
WHO Classification of tumours of haematopoietic and lymphoid tissuesLyon: IARC, 2
A. Younes, N. Bartlett, J. Leonard, D. Kennedy, C. Lynch, E. Sievers, A. Forero-Torres (2010)
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.The New England journal of medicine, 363 19
F. d'Amore, Maria Silva, S. Leppä, T. Relander, A. Pezzutto, G. Lauritzsen, E. Weidmann, M. Gelder, M. Merup, H. Hagberg, U. Fagerli, P. Brown, P. Hansen, J. Mariz, M. Jankovska, J. Walewski, J. Doorduijn, A. Hoof, I. Christiansen, S. Jyrkkiö, J. Kluin-Nelemans, M. Kooy, R. Fijnheer, W. Stevens, J. Zijlstra, L. Bohmer, P. Lugtenburg, M. Grube, V. Procházka, D. Šálek, R. Greil, L. Trümper, G. Wulf, B. Altmann, M. Ziepert, M. Loeffler, E. Jantunen, G. Hopfinger, E. Neste, Helle Toldbod (2011)
First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell TransplantBlood, 118
J. Friedberg, D. Mahadevan, JungAh Jung, D. Persky, I. Lossos, H. Danaee, Xiaofei Zhou, E. Leonard, S. Bernstein (2011)
Phase 2 Trial of Alisertib (MLN8237), An Investigational, Potent Inhibitor of Aurora A Kinase (AAK), in Patients (pts) with Aggressive B- and T-Cell Non-Hodgkin Lymphoma (NHL)Blood, 118
S. Werwitzke, M. Hornung, Katy Kalippke, A. Trummer, A. Ganser, A. Tiede (2011)
Deletion or Inhibition of Fc Gamma Receptor IIb (CD32) Prevents the Memory B Cell Response to Factor VIII in a Hemophilia A Mouse ModelBlood, 118
G. Adams, G. Larusch, A. Schmaier (2011)
Prolylcarboxypeptidase Promotes Endothelial Cell Proliferation and Vascular RepairBlood, 118
O. Merkel, F. Hamacher, D. Laimer, E. Sifft, Z. Trajanoski, M. Scheideler, G. Egger, M. Hassler, C. Thallinger, Ana-Iris Schmatz, S. Turner, R. Greil, L. Kenner (2010)
Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK− anaplastic large-cell lymphomaProceedings of the National Academy of Sciences, 107
N. Schmitz, L. Trümper, M. Ziepert, M. Nickelsen, A. Ho, B. Metzner, N. Peter, M. Loeffler, A. Rosenwald, M. Pfreundschuh (2010)
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.Blood, 116 18
J. Vose, J. Armitage, D. Weisenburger (2008)
International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 25
F. Foss, P. Zinzani, J. Vose, R. Gascoyne, S. Rosen, K. Tobinai (2011)
Peripheral T-cell lymphoma.Blood, 117 25
T. Tang, George Allen, Ghee Koo, K. Tay, D. Tan, R. Quek, M. Tao, S. Tan, B. Teh, S. Lim (2011)
Gene Expression Profiling Identifies the JAK/STAT and NFκB Pathways to Be Important in Peripheral T-Cell Lymphomas and Natural-Killer T-Cell LymphomasBlood, 118
Jong Kim, S. Sohn, Y. Chae, Y. Cho, Deok-Hwan Yang, Je-Jung Lee, Hyeoung-Joon Kim, Ho-Jin Shin, J. Chung, G. Cho, W. Lee, Y. Joo, C. Sohn, Sukjoong Oh (2007)
Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II studyCancer Chemotherapy and Pharmacology, 60
E. Martín-Sánchez, S. Rodríguez-Pinilla, M. Sánchez-Beato, L. Lombardía, Beatriz Domínguez-González, D. Romero, L. Odqvist, P. García-Sanz, M. Wozniak, G. Kurz, C. Blanco-Aparicio, M. Mollejo, F. Alves, J. Menárguez, F. González‐Palacios, J. Rodríguez-Peralto, P. Ortiz-Romero, Juan García, J. Bischoff, M. Piris (2012)
Simultaneous pan-PI 3 K and MEK inhibition as a potential therapeutic strategy in peripheral T cell lymphomas
C. Iancu-Rubin, D. Gajzer, G. Mosoyan, J. Mascarenhas, R. Hoffman (2011)
Panobinostat (LBH589)-Mediated Acetylation of Tubulin Plays a Role in Megakaryocyte Maturation and Platelet ReleaseBlood, 118
S. Chu, Diane Heiser, Li Li, I. Kaplan, D. Huso, C. Civin, D. Small (2011)
FLT3-ITD Knock-in Impairs Hematopoietic Stem Cell Quiescence/Homeostasis, Leading to a Myeloproliferative NeoplasmBlood, 118
E Martin-Sanchez, SM Rodriguez-Pinilla, L Lombardia, B Dominguez-Gonzalez, M Sanchez-Beato, D Romero (2011)
PI3 K inhibition as a potential therapeutic strategy in peripheral T-cell lymphomasBlood, 118
Treating peripheral T-cell lymphomas (PTCL) remains a clinical challenge harbouring an often aggressive course and furthermore, no standard therapy is established. In more detail, PTCL comprises a heterogeneous group of haematological tumours constituting less than 15 % of all non-Hodgkin’s lymphomas (NHLs) in adults in the western hemisphere. The following short review will provide an up-date based on data presented at ASH meeting 2011 in PTCL providing improved understanding of patho-mechanism and further development of more specific therapy options.
memo - Magazine of European Medical Oncology – Springer Journals
Published: Aug 18, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.